Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Boosted by Boothbay Fund Management LLC

Boothbay Fund Management LLC grew its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 71.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 447,019 shares of the biopharmaceutical company’s stock after purchasing an additional 185,798 shares during the quarter. Boothbay Fund Management LLC’s holdings in Agios Pharmaceuticals were worth $14,868,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Brevan Howard Capital Management LP acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $970,000. Bellevue Group AG grew its holdings in Agios Pharmaceuticals by 2.1% during the second quarter. Bellevue Group AG now owns 3,590,150 shares of the biopharmaceutical company’s stock worth $119,408,000 after acquiring an additional 75,000 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Agios Pharmaceuticals by 6.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 791,000 shares of the biopharmaceutical company’s stock worth $26,309,000 after acquiring an additional 48,000 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Agios Pharmaceuticals by 11.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 52,252 shares of the biopharmaceutical company’s stock valued at $1,738,000 after acquiring an additional 5,441 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its holdings in Agios Pharmaceuticals by 71.4% in the 2nd quarter. Orbimed Advisors LLC now owns 557,900 shares of the biopharmaceutical company’s stock valued at $18,556,000 after acquiring an additional 232,400 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on AGIO. Wall Street Zen cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. Bank of America decreased their price target on shares of Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, November 20th. The Goldman Sachs Group dropped their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Finally, Leerink Partners raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and reduced their price objective for the stock from $40.00 to $34.00 in a research note on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.78.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $27.27 on Friday. The company has a 50-day moving average of $36.76 and a two-hundred day moving average of $36.66. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -3.90 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s revenue was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $16.22 earnings per share. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $43.92, for a total value of $145,023.84. Following the completion of the sale, the insider owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This trade represents a 5.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Cecilia Jones sold 3,651 shares of Agios Pharmaceuticals stock in a transaction on Friday, September 26th. The shares were sold at an average price of $36.77, for a total value of $134,247.27. Following the transaction, the chief financial officer owned 33,870 shares in the company, valued at $1,245,399.90. This represents a 9.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 7,553 shares of company stock worth $305,001. Corporate insiders own 4.30% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.